Cannabidiol (Kanbis)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged 2... (AR)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Lennox-Gastaut SyndromeDravet Syndrome

Also approved (1)
AR
  • Seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged 2 years and older (Kanbis, Laboratorio Elea)
Product first approved 2021pharmabiz.net

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Parkinson's Disease

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Dravet Syndrome: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cannabidiol (Kanbis): this drugStage not on recordSmall moleculecannabinoidnot yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
NCT02926898: Change in monthly convulsive seizure frequency over titration plus maintenance, fenfluramine 0.4 mg/kg/day (n=43) vs placebo (n=44), in Dravet syndrome on stiripentol-inclusive regimens: 54.0% greater reduction with fenfluramine (95% CI 35.6% to 67.2%); ANCOVA p<0.001 (CT.gov posted analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
ZorevunersenPhase 3RNA / oligonucleotideSCN1A mRNAWeak signalNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)
Phase 2/3(overall)
Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoid
not yet graded(overall)
No reviewed efficacy summary in this indication
Huperzine A (SPN-817)
Phase 2(overall)
Small moleculeAcetylcholinesterasenot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.